CN116648246A - 包含氟马西尼和纳曲酮的组合物及其使用方法 - Google Patents

包含氟马西尼和纳曲酮的组合物及其使用方法 Download PDF

Info

Publication number
CN116648246A
CN116648246A CN202180078969.9A CN202180078969A CN116648246A CN 116648246 A CN116648246 A CN 116648246A CN 202180078969 A CN202180078969 A CN 202180078969A CN 116648246 A CN116648246 A CN 116648246A
Authority
CN
China
Prior art keywords
naltrexone
flumazenil
micrograms
combination
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180078969.9A
Other languages
English (en)
Chinese (zh)
Inventor
L·E·罗德尼
D·J·扎纳尔杜
J·奇克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Treze Pharmaceuticals Private Ltd
Original Assignee
Treze Pharmaceuticals Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904390A external-priority patent/AU2020904390A0/en
Application filed by Treze Pharmaceuticals Private Ltd filed Critical Treze Pharmaceuticals Private Ltd
Priority to CN202610170303.0A priority Critical patent/CN121695144A/zh
Publication of CN116648246A publication Critical patent/CN116648246A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180078969.9A 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法 Pending CN116648246A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202610170303.0A CN121695144A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904390 2020-11-27
AU2020904390A AU2020904390A0 (en) 2020-11-27 Compositions and methods
PCT/AU2021/051413 WO2022109677A1 (en) 2020-11-27 2021-11-26 Compositions comprising flumazenil and naltrexone and methods for use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202610170303.0A Division CN121695144A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Publications (1)

Publication Number Publication Date
CN116648246A true CN116648246A (zh) 2023-08-25

Family

ID=81753640

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180078969.9A Pending CN116648246A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法
CN202610170303.0A Pending CN121695144A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202610170303.0A Pending CN121695144A (zh) 2020-11-27 2021-11-26 包含氟马西尼和纳曲酮的组合物及其使用方法

Country Status (9)

Country Link
US (2) US12521401B2 (https=)
EP (1) EP4251168A4 (https=)
JP (1) JP2024501919A (https=)
KR (1) KR20230110793A9 (https=)
CN (2) CN116648246A (https=)
AU (2) AU2021388076B2 (https=)
CA (1) CA3201498A1 (https=)
IL (1) IL303117A (https=)
WO (1) WO2022109677A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106574A1 (en) * 2023-11-14 2025-05-22 Aardwolf Therapeutics, Inc. Flumazenil for treating post-traumatic stress disorder and anxiety

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008538748A (ja) 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
ES2289935B1 (es) 2006-07-14 2008-12-16 Juan Jose Legarda Ibañez Empleo de flumazenilo en la elaboracion de un medicamento para el tratamiento de la patologia depresiva.
US9283212B2 (en) * 2009-02-20 2016-03-15 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
US20150111916A9 (en) * 2010-04-29 2015-04-23 Annette Channa Toledano Treatment of pain using a composition of opioid/Toll-like receptor 4 antagonists and dextro enantiomers thereof
WO2014120936A2 (en) * 2013-01-30 2014-08-07 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent
WO2014186824A1 (en) * 2013-05-20 2014-11-27 Palmaya Pty Ltd Treatment of neurological and other disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160256472A1 (en) * 2013-10-14 2016-09-08 Palmaya Pty Ltd Compositions and methods of administering same
WO2020181340A1 (en) * 2019-03-14 2020-09-17 Palmaya Pty Ltd Treatment of inflammatory diseases of the central nervous system

Also Published As

Publication number Publication date
AU2021388076A9 (en) 2024-08-08
CN121695144A (zh) 2026-03-20
AU2021388076B2 (en) 2025-08-14
US20240000796A1 (en) 2024-01-04
WO2022109677A1 (en) 2022-06-02
EP4251168A1 (en) 2023-10-04
CA3201498A1 (en) 2022-06-02
JP2024501919A (ja) 2024-01-17
IL303117A (en) 2023-07-01
EP4251168A4 (en) 2024-11-06
AU2025267401A1 (en) 2025-12-04
KR20230110793A (ko) 2023-07-25
US20260102405A1 (en) 2026-04-16
KR20230110793A9 (ko) 2024-11-13
US12521401B2 (en) 2026-01-13
AU2021388076A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US12453726B2 (en) Methods of using factor B inhibitors
US11406632B2 (en) Aripiprazole formulations having increased injection speeds
US8309535B2 (en) Compositions and methods to treat recurrent medical conditions
CN102133171A (zh) 延缓释放阿立哌唑的可注射组合物
US20030181462A1 (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
CN105579018A (zh) 预制备用于治疗用途的药物的方法
CN110013478A (zh) 用于抗肿瘤试剂施用的方法
AU2025267401A1 (en) Compositions comprising flumazenil and naltrexone and methods for use thereof
RU2268725C2 (ru) Комбинация лекарственных препаратов, включающая миртазапин, для лечения депрессии и связанных расстройств
EP2670405B1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
US8877740B2 (en) Compound composition for inhalation used for treating asthma
US20170065579A1 (en) Sustained Release Low Dose Formulations and Uses Thereof
JP6702883B2 (ja) 向神経活性ペプチドの安定な組成物
US20110301102A1 (en) Compositions and methods for treating myelodysplastic syndrome
CA3258070A1 (en) SUBCUTANEOUS ADMINISTRATION OF ONFASPRODIL AND DOSING METHODS INTENDED FOR USE IN THE TREATMENT OF DEPRESSIVE DISORDERS
TW202102211A (zh) 用於使用６，８－雙－苄硫基－辛酸治療淋巴瘤之治療方法及組成物
JP2013541575A (ja) 増殖性疾患の治療のためのベバシズマブと２，２−ジメチル−Ｎ−（（Ｓ）−６−オキソ−６，７−ジヒドロ−５Ｈ−ジベンゾ［ｂ，ｄ］アゼピン−７−イル）−Ｎ’−（２，２，３，３，３−ペンタフルオロ−プロピル）−マロンアミドの併用
WO2022123607A1 (en) Pharmaceutical formulations of esketamine
Мелешко et al. Pharmacology: practical manual
KR20240056487A (ko) 고형 종양을 치료하기 위한 약제학적 조성물
CN115919767A (zh) 卡巴拉汀鼻喷雾剂及其制备方法
WO2005097138A2 (en) Combinations comprising oxcarbazepine to treat affective disorders
TW201306832A (zh) 用於治療骨髓發育不良症候群的組成物及方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination